PT-141
Also: Bremelanotide · Vyleesi
Centrally-acting libido peptide — FDA-approved for premenopausal HSDD.
Evidence
established
Legal status
rx only
Half-life
~2 hours
Routes
subq · nasal
What it is
PT-141 is approved (as Vyleesi) for hypoactive sexual desire disorder in premenopausal women. Unlike PDE5 inhibitors, it works centrally on desire rather than peripherally on vascular flow. Used off-label by both sexes.
Mechanism
MC4R agonist that acts centrally on sexual desire pathways, independently of vascular flow.
Outcomes it's matched to
- STRENGTH90%
Safety
Nausea, flushing, and transient blood-pressure increase reported.
- Uncontrolled hypertension
- Cardiovascular disease
Legal context
Prescription medication.